CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
CD5024 0.3% cream +1 moredrug
Likely dose
CD5024 0.3% cream 2 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03250624
NCT03250624Phase 2Completed
CompareCT.gov

Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

Galderma R&D·interventional·Posted Aug 15, 2017·Updated May 1, 2023

In Brief

A Phase 2 clinical trial evaluating CD5024 0.3% cream and Placebo for Atopic Dermatitis. Completed, enrolled 63 participants across 5 sites.

Detailed Summary

Exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel group study, involved participants with chronic lesions of Atopic Dermatitis (AD) to evaluate the local and systemic safety of CD5024 0.3% cream over a 6-week treatment period compared to its vehicle.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 15, 2017
Enrollment StartNov 1, 2016
Primary CompletionJun 26, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.9 years ago

Interventions

CD5024 0.3% creamdrug

Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.

Placebodrug

Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.